Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK, de Lemos JA: Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007, 99(4):513-518. doi:10.1016/j.amjcard.2006.08.064
Article
Google Scholar
Anand DV, Lahiri A, Lim E, Hopkins D, Corder R: The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006, 47(9):1850-1857. doi:10.1016/j.jacc.2005.12.054
Article
Google Scholar
Andersen GO, Knudsen EC, Aukrust P, Yndestad A, Oie E, Muller C, Seljeflot I, Ueland T: Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart 2011, 97(6):460-465. doi:10.1136/hrt.2010.206714
Article
Google Scholar
Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM, Giachelli CM, Rosenfeld ME: Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 2006, 26(9):2117-2124. doi:10.1161/01.ATV.0000236428.91125.e6
Article
Google Scholar
Biscetti F, Straface G, Giovannini S, Santoliquido A, Angelini F, Santoro L, Porreca CF, Pecorini G, Ghirlanda G, Flex A: Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients. Hum Gen 2013, 132(1):49-55. doi:10.1007/s00439-012-1224-9
Article
Google Scholar
Brandstrom H, Stiger F, Lind L, Kahan T, Melhus H, Kindmark A: A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. Biochem Biophys Res Commun 2002, 293(1):13-17. doi:10.1016/S0006-291× (02) 00137-7
Article
Google Scholar
Browner WS, Lui LY, Cummings SR: Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001, 86(2):631-637. 10.1210/jc.86.2.631
Google Scholar
Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12(9):1260-1268. 10.1101/gad.12.9.1260
Article
Google Scholar
Chan BY, Buckley KA, Durham BH, Gallagher JA, Fraser WD: Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. Clin Chem 2003, 49(12):2083-2085. doi:10.1373/clinchem.2003.023747
Article
Google Scholar
Chen WJ, Rijzewijk LJ, van der Meer RW, Heymans MW, van Duinkerken E, Lubberink M, Lammertsma AA, Lamb HJ, de Roos A, Romijn JA, Smit JW, Bax JJ, Bjerre M, Frystyk J, Flyvbjerg A, Diamant M: Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men. Cardiovasc Diabetol 2011, 10: 67. doi:10.1186/1475-2840-10-67
Article
Google Scholar
Chollet ME, Brouland JP, Bal dit Sollier C, Bauduer F, Drouet L, Bellucci S: Evidence of a colocalisation of osteoprotegerin (OPG) with von Willebrand factor (VWF) in platelets and megakaryocytes alpha granules. Studies from normal and grey platelets. Br J Haematol 2010, 148(5):805-807. doi:10.1111/j.1365-2141.2009.07989.x
Article
Google Scholar
Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, Tordoir JH, Spronk HM, Vermeer C, Daemen MJ: Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001, 21(12):1998-2003. 10.1161/hq1201.100229
Article
Google Scholar
Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998, 273(23):14363-14367. 10.1074/jbc.273.23.14363
Article
Google Scholar
Flyvbjerg A: Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol 2010, 6(2):94-101. doi:10.1038/nrendo.2009.266
Article
Google Scholar
Fuernau G, Zaehringer S, Eitel I, de Waha S, Droppa M, Desch S, Schuler G, Adams V, Thiele H: Osteoprotegerin in ST-elevation myocardial infarction: Prognostic impact and association with markers of myocardial damage by magnetic resonance imaging. Int J Cardiol 2012. doi:10.1016/j.ijcard.2012.05.101
Google Scholar
Galluzzi F, Stagi S, Salti R, Toni S, Piscitelli E, Simonini G, Falcini F, Chiarelli F: Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. Eur J Endocrinol 2005, 153(6):879-885. doi:10.1530/eje.1.02052
Article
Google Scholar
Gordin D, Soro-Paavonen A, Thomas MC, Harjutsalo V, Saraheimo M, Bjerre M, Forsblom C, Flyvbjerg A, Groop PH, FinnDiane Study G: Osteoprotegerin is an independent predictor of vascular events in finnish adults with type 1 diabetes. Diabetes Care 2013, 36(7):1827-1833. doi:10.2337/dc12-2170
Article
Google Scholar
Hansen HH, Joensen AM, Riahi S, Malczynski J, Molenberg D, Ravkilde J: Short and long-term outcome in diabetic patients with acute myocardial infarction in the invasive era. Scand Cardiovasc J 2007, 41(1):19-24. doi:10.1080/14017430601099238
Article
Google Scholar
Heinonen SE, Leppanen P, Kholova I, Lumivuori H, Hakkinen SK, Bosch F, Laakso M, Yla-Herttuala S: Increased atherosclerotic lesion calcification in a novel mouse model combining insulin resistance, hyperglycemia, and hypercholesterolemia. Circ Res 2007, 101(10):1058-1067. doi:10.1161/CIRCRESAHA.107.154401
Article
Google Scholar
Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292(4):490-495. doi:10.1001/jama.292.4.490
Article
Google Scholar
Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O’Brien T, Khosla S: Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001, 280(1):334-339. doi:10.1006/bbrc.2000.4130
Article
Google Scholar
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(15):1577-1589. doi:10.1056/NEJMoa0806470
Article
Google Scholar
Jorgensen GM, Vind B, Nybo M, Rasmussen LM, Hojlund K: Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity. Eur J Endocrinol 2009, 161(1):95-101. doi:10.1530/EJE-09-0141
Article
Google Scholar
Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM: Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 2008, 51(11):2100-2107. doi:10.1007/s00125-008-1123-8
Article
Google Scholar
Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J: Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109(18):2175-2180. doi:10.1161/01.CIR.0000127957.43874.BB
Article
Google Scholar
Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G: The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006, 4(6):801-811. doi:10.1586/14779072.4.6.801
Article
Google Scholar
Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM: Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003, 149(1):39-42. 10.1530/eje.0.1490039
Article
Google Scholar
Logstrup BB, Hofsten DE, Christophersen TB, Moller JE, Bjerre M, Flyvbjerg A, Botker HE, Egstrup K: Microvascular dysfunction is associated with plasma osteoprotegerin levels in patients with acute myocardial infarction. Coron Artery Dis 2013, 24(6):487-492. doi:10.1097/MCA.0b013e328363242e
Article
Google Scholar
Mazzone T, Chait A, Plutzky J: Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008, 371(9626):1800-1809. doi:10.1016/S0140-6736(08)60768-0
Article
Google Scholar
Mogelvang R, Pedersen SH, Flyvbjerg A, Bjerre M, Iversen AZ, Galatius S, Frystyk J, Jensen JS: Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis. Am J Cardiol 2012, 109(4):515-520. doi:10.1016/j.amjcard.2011.09.043
Article
Google Scholar
Mogelvang R, Haahr-Pedersen S, Bjerre M, Frystyk J, Iversen A, Galatius S, Flyvbjerg A, Jensen JS: Osteoprotegerin improves risk detection by traditional cardiovascular risk factors and hsCRP. Heart 2013, 99(2):106-110. doi:10.1136/heartjnl-2012-302240
Article
Google Scholar
Montagnana M, Lippi G, Danese E, Guidi GC: The role of osteoprotegerin in cardiovascular disease. Ann Med 2013, 45(3):254-264. doi:10.3109/07853890.2012.727019
Article
Google Scholar
Montecucco F, Steffens S, Mach F: The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? Clin Dev Immunol 2007, 2007: 75805. doi:10.1155/2007/75805
Article
Google Scholar
Mosheimer BA, Kaneider NC, Feistritzer C, Djanani AM, Sturn DH, Patsch JR, Wiedermann CJ: Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab 2005, 90(5):2964-2971. doi:10.1210/jc.2004-1895
Article
Google Scholar
Nybo M, Rasmussen LM: The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 2008, 159(5):603-608. doi:10.1530/EJE-08-0554
Article
Google Scholar
Nybo M, Rasmussen LM: Osteoprotegerin released from the vascular wall by heparin mainly derives from vascular smooth muscle cells. Atherosclerosis 2008, 201(1):33-35. doi:10.1016/j.atherosclerosis.2008.03.026
Article
Google Scholar
Olesen P, Ledet T, Rasmussen LM: Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 2005, 48(3):561-568. doi:10.1007/s00125-004-1652-8
Article
Google Scholar
Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, de Lemos JA: Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007, 49(6):1392-1398. doi:10.1161/HYPERTENSIONAHA.107.087742
Article
Google Scholar
Pedersen S, Mogelvang R, Bjerre M, Frystyk J, Flyvbjerg A, Galatius S, Sorensen TB, Iversen A, Hvelplund A, Jensen JS: Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiology 2012, 123(1):31-38. doi:10.1159/000339880
Article
Google Scholar
Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A: Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006, 154(1):75-81. doi:10.1530/eje.1.02049
Article
Google Scholar
Redgrave JN, Lovett JK, Syed AB, Rothwell PM: Histological features of symptomatic carotid plaques in patients with impaired glucose tolerance and diabetes (oxford plaque study). Cerebrovasc Dis 2008, 26(1):79-86. doi:10.1159/000136900
Article
Google Scholar
Reid P, Holen I: Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol 2009, 88(1):1-17. doi:10.1016/j.ejcb.2008.06.004
Article
Google Scholar
Reinhard H, Lajer M, Gall MA, Tarnow L, Parving HH, Rasmussen LM, Rossing P: Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care 2010, 33(12):2561-2566. doi:10.2337/dc10-0858
Article
Google Scholar
Roysland R, Masson S, Omland T, Milani V, Bjerre M, Flyvbjerg A, Di Tano G, Misuraca G, Maggioni AP, Tognoni G, Tavazzi L, Latini R: Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. Am Heart J 2010, 160(2):286-293. doi:10.1016/j.ahj.2010.05.015
Article
Google Scholar
Roysland R, Bonaca MP, Omland T, Sabatine M, Murphy SA, Scirica BM, Bjerre M, Flyvbjerg A, Braunwald E, Morrow DA: Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart 2012, 98(10):786-791. doi:10.1136/heartjnl-2011-301260
Article
Google Scholar
Schoppet M, Preissner KT, Hofbauer LC: RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002, 22(4):549-553. 10.1161/01.ATV.0000012303.37971.DA
Article
Google Scholar
Schoppet M, Al-Fakhri N, Franke FE, Katz N, Barth PJ, Maisch B, Preissner KT, Hofbauer LC: Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg’s sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004, 89(8):4104-4112. doi:10.1210/jc.2003-031432
Article
Google Scholar
Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp-Pedersen C: Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008, 117(15):1945-1954. doi:10.1161/CIRCULATIONAHA.107.720847
Article
Google Scholar
Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89(2):309-319. 10.1016/S0092-8674(00)80209-3
Article
Google Scholar
Singh DK, Winocour P, Summerhayes B, Viljoen A, Sivakumar G, Farrington K: Low serum osteoprotegerin levels in normoalbuminuric type 1 diabetes mellitus. Acta Diabetol 2010, 47(Suppl 1):105-110. doi:10.1007/s00592-009-0146-z
Article
Google Scholar
Soufi M, Schoppet M, Sattler AM, Herzum M, Maisch B, Hofbauer LC, Schaefer JR: Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab 2004, 89(8):3764-3768. doi:10.1210/jc.2003-032054
Article
Google Scholar
Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A: Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002, 100(8):3002-3007. doi:10.1182/blood-2002-04-1190
Article
Google Scholar
Straface G, Biscetti F, Pitocco D, Bertoletti G, Misuraca M, Vincenzoni C, Snider F, Arena V, Stigliano E, Angelini F, Iuliano L, Boccia S, de Waure C, Giacchi F, Ghirlanda G, Flex A: Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability. Stroke 2011, 42(11):3022-3028. doi:10.1161/STROKEAHA.111.619288
Article
Google Scholar
Theoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, Fortun Y, Padrines M, Redini F, Heymann D: Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem Biophys Res Commun 2006, 347(2):460-467. doi:10.1016/j.bbrc.2006.06.120
Article
Google Scholar
Vaccarezza M, Bortul R, Fadda R, Zweyer M: Increased OPG expression and impaired OPG/TRAIL ratio in the aorta of diabetic rats. Med Chem 2007, 3(4):387-391. 10.2174/157340607781024456
Article
Google Scholar
Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S: Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009, 32(Suppl 2):S314-S321. doi:10.2337/dc09-S330
Article
Google Scholar
Vik A, Brodin E, Sveinbjornsson B, Hansen JB: Heparin induces mobilization of osteoprotegerin into the circulation. Thromb Haemost 2007, 98(1):148-154.
Google Scholar
Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njolstad I, Jorgensen L, Hansen JB: Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study. J Thromb Haemost 2011, 9(4):638-644. doi:10.1111/j.1538-7836.2011.04222.x
Article
Google Scholar
Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, Higashio K: Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998, 273(9):5117-5123. 10.1074/jbc.273.9.5117
Article
Google Scholar
Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, Gamble J, To LB, Findlay DM, Haynes DR: Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 2005, 204(2):714-723. doi:10.1002/jcp.20354
Article
Google Scholar